ZYPREXA 10 MG
OLANZAPINE : 10 MG · DIN 02229285 · CHEPLAPHARM REGISTRATION GMBH
Health Canada status: MARKETED
What is ZYPREXA?
ZYPREXA 10 MG contains OLANZAPINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02229285, held by CHEPLAPHARM REGISTRATION GMBH, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 30-Jan-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZYPREXA used for?
Acute and maintenance treatment of schizophrenia and related psychotic disorders; acute treatment of manic or mixed episodes in bipolar I disorder; rapid control of agitation in schizophrenia/mania (IM).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02229285 |
|---|---|
| Brand name | ZYPREXA |
| Generic / active ingredient | OLANZAPINE : 10 MG |
| Manufacturer | CHEPLAPHARM REGISTRATION GMBH |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AH03 OLANZAPINE |
| AHFS class | 28:16.08.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 30-Jan-2025 |
| Original market date | 1996-11-14 00:00:00 |
How is it administered?
Oral: 5-20 mg once daily. IM: 10 mg initial dose (5-7.5 mg based on status); max 3 injections/24h, max 20 mg total daily dose (oral + IM). Reconstitute IM with 2.1 mL Sterile Water.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted IM: Store at 20°C-25°C for up to 1 hour. (General storage for tablets not explicitly detailed in provided snippet, but IM reconstitution storage is specified).
How is it supplied?
Tablets: Bottles (7, 30, 60, 100, 250, 1000) and blisters. ZYDIS: Aluminum blister strips (7 or 28 tablets). IM: 5 mL single-use vials.
Contraindications
Hypersensitivity to olanzapine or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Warnings and precautions
Increased mortality in elderly patients with dementia. Risk of Neuroleptic Malignant Syndrome, Tardive Dyskinesia, orthostatic hypotension, falls, and anticholinergic effects.
Is OLANZAPINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05AH03 OLANZAPINE. 103 of 271 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OLANZAPINE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02281821 |
| APO-OLANZAPINE | 15 MG | TABLET | APOTEX INC | MARKETED | DIN 02281848 |
| APO-OLANZAPINE | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02281791 |
| APO-OLANZAPINE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02333015 |
| APO-OLANZAPINE | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02281805 |
| APO-OLANZAPINE | 7.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02281813 |
| APO-OLANZAPINE ODT | 10 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360624 |
| APO-OLANZAPINE ODT | 15 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360632 |
| APO-OLANZAPINE ODT | 20 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360640 |
| APO-OLANZAPINE ODT | 5 MG | TABLET (ORALLY DISINTEGRATING) | APOTEX INC | MARKETED | DIN 02360616 |
Who else supplies OLANZAPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OLANZAPINE appears in 1801 registered pack listings across 15 markets, published on 13 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.